Published in Vaccine Weekly, April 5th, 2006
Under the terms of the agreement, BBIL will fund 100% of the preclinical and clinical studies for these markets and assist in developing an efficient manufacturing process for the virus-like particle (VLP) based influenza vaccine. BBIL will be responsible for the sale and distribution of the vaccine in India and other surrounding countries. Novavax will receive unrestricted access to all preclinical and clinical data generated by BBIL and will receive a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly